Cargando…

The clinical impact of CYP2C19 2 and 3 polymorphism on Clopidogrel and cost analysis

Detalles Bibliográficos
Autores principales:	Meman A, Al, H, Khalaf, Seemab, Rasool
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075508/ http://dx.doi.org/10.1186/1471-2164-15-S2-P19

Ejemplares similares

The impact of CYP2C19 *2 and *3 polymorphism on clopidogrel response following coronary stenting in Saudi patients with acute coronary syndrome
por: H, Khalaf, et al.
Publicado: (2014)

Impact of Cytochrome P450 2C19* 2 and * 3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome
por: Khalaf, Hassan, et al.
Publicado: (2016)

Impact of CYP2B6 and CYP2A6 polymorphisms on efavirenz plasma concentrations in Ghanaian HIV-infected patients
por: Zhang, Y, et al.
Publicado: (2010)

Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients
por: Zhuo, Zhong-ling, et al.
Publicado: (2018)

Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients
por: Li, Changqing, et al.
Publicado: (2021)

Comment on “Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients”
por: Wang, Bin, et al.
Publicado: (2018)

CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors
por: Sukasem, Chonlaphat, et al.
Publicado: (2013)

Polymorfism Of CYP2C9 And 3A5 and carbamazepine hypersensitivity reactions in Brazilian subjects
por: Tanno, Luciana, et al.
Publicado: (2014)

Polymorfism Of CYP2C9 And 3A5 and carbamazepine hypersensitivity reactions in Brazilian subjects
por: Tanno, Luciana, et al.
Publicado: (2014)

Association of CYP2C19 Polymorphism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China
por: Su, Qiang, et al.
Publicado: (2019)

Impacts of CYP2C19 Polymorphism and Clopidogrel Dosing on in-Stent Restenosis: A Retrospective Cohort Study in Chinese Patients
por: Zhang, Min, et al.
Publicado: (2020)

Does clopidogrel change morbidity and mortality in ICU sepsis patients?
por: Klepser, DG, et al.
Publicado: (2014)

Prevalence of CYP2C9 and CYP2C19 variants and the impact on clopidogrel efficacy in patients having CYPC19*2 variant
por: Mehta, Meha P., et al.
Publicado: (2023)

A family based study on T-C transition polymorphism in Cyp17a1 gene in Indian children
por: Gayan, Sukanya, et al.
Publicado: (2014)

The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel
por: Pettersen, Alf-Aage R, et al.
Publicado: (2011)

Association of CYP2C19 Polymorphisms with the Clinical Efficacy of Clopidogrel Therapy in Patients Undergoing Carotid Artery Stenting in Asia
por: Zhu, Wen-Yao, et al.
Publicado: (2016)

Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients
por: Marchini, J.F.M., et al.
Publicado: (2017)

Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
por: Brown, Sherry-Ann, et al.
Publicado: (2018)

CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic
por: Mirabbasi, Seyed abbas, et al.
Publicado: (2017)

Simultaneous Two-Vessel Subacute Stent Thrombosis Caused by Clopidogrel Resistance from CYP2C19 Polymorphism
por: Afzal, Ashwad, et al.
Publicado: (2016)

Pharmacogenetics of CYP2C19 genetic polymorphism on clopidogrel response in patients with ischemic stroke from Saudi Arabia
por: Alhazzani, Adel A., et al.
Publicado: (2017)

Influence of CYP3A5 polymorphism on tacrolimus drug dosing in Indian renal allograft recipients: initial experience
por: Patel, Mohan, et al.
Publicado: (2014)

Postmenstrual age and CYP2D6 polymorphisms determine urinary tramadol O-demethylation excretion in critically ill neonates and infants
por: Allegaert, K, et al.
Publicado: (2008)

ABCB1 C3435T and CYP2C19*2 polymorphisms in a Palestinian and Turkish population: A pharmacogenetic perspective to clopidogrel
por: Nassar, Suheir, et al.
Publicado: (2014)

Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice
por: Russmann, Stefan, et al.
Publicado: (2020)

Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke
por: Rath, Charlotte Lützhøft, et al.
Publicado: (2020)

Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel
por: Danielak, Dorota, et al.
Publicado: (2016)

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis
por: Bauer, Tim, et al.
Publicado: (2011)

The correlation between recurrent risk and CYP2C19 gene polymorphisms in patients with ischemic stroke treated with clopidogrel for prevention
por: Liu, Guohua, et al.
Publicado: (2020)

CYP2C19 polymorphisms and lipoproteins associated with clopidogrel resistance in children with Kawasaki disease in China: A prospective study
por: Zhang, Mingming, et al.
Publicado: (2022)

Relationship between CYP2C19 Polymorphism and Clopidogrel Resistance in Patients with Coronary Heart Disease and Ischemic Stroke in China
por: Chang, Rong, et al.
Publicado: (2022)

CYP2C19 Polymorphism in Ischemic Heart Disease Patients Taking Clopidogrel After Percutaneous Coronary Intervention in Egypt
por: Shawky, Ahmed, et al.
Publicado: (2023)

CYP2E1 and Parkinson’s disease in a MPTP-induced C57BL/6 mouse model
por: Basaran, Rahman, et al.
Publicado: (2013)

Pharmacogenetics of CYP3A5 on Carbamazepine pharmacokinetics in epileptic patients developing toxicity
por: Al-Gahtany, Mubarak, et al.
Publicado: (2014)

Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults
por: Sridharan, Kannan, et al.
Publicado: (2016)

Impact of KCNJ11, TCF7L2, SLC30A8, IGF2BP2, PPARG, SLC47A1, STK11, HHEX, KCNQ1, CDKAL1, FTO, CYP2C9, ADIPOQ, CAPN10 gene polymorphisms on risk of type 2 diabetes and therapeutic response to sulfonylurea and metformin therapy
por: Phani, Nagaraja, et al.
Publicado: (2014)

Correlation study of CYP2C19 gene polymorphism and clopidogrel resistance in Han Chinese patients with cerebral infarction in Guizhou region
por: Shi, Guo-Xian, et al.
Publicado: (2021)

Analysis of CYP2C19 gene polymorphism and influencing factors of pharmacological response of clopidogrel in patients with cerebral infarction in Zhejiang, China
por: Mo, Yijun, et al.
Publicado: (2023)

Effects of CYP2C19 and P2Y12 Gene Polymorphisms on Clinical Results of Patients Using Clopidogrel after Acute Ischemic Cerebrovascular Disease
por: Sen, HM, et al.
Publicado: (2015)

CYP2B6*18 is associated with nevirpine hypersensitivity independently of HLA-C*04:01 in a Malawian HIV population
por: Carr, Daniel, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tqv67e2mrvuu4pjin3auaqsr8u